PharmTech.com notes that abuse-resistant pain drugs are a hot area of development right now. Author Patrician Van Arnum brings up Pfizer's recent $3.6 billion purchase of King Pharmaceuticals for its drug-delivery technology that discourages abuse of painkillers. The article provides a decent overview of King's pipeline of abuse-deterrent medication and the reason for Pfizer's interest. "King's leadership in new formulations of pain treatments designed to discourage common methods of misuse and abuse will provide Pfizer with multiple drug-delivery platforms while providing potential long-term upside," Pfizer said in a release in October. PharmTech's report